CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Naltrexone plus N-Acetyl Cysteine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00332605
NCT00332605Phase 2Completed
CompareCT.gov

A Double-Blind Study of N-Acetyl Cysteine Plus Naltrexone in the Treatment of Methamphetamine Dependence

University of Chicago·interventional·Posted Jun 1, 2006·Updated Aug 23, 2022

In Brief

A Phase 2 clinical trial evaluating Naltrexone plus N-Acetyl Cysteine and Placebo for Methamphetamine Dependence. Completed, enrolled 45 participants across 1 site.

Detailed Summary

The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in combination with naltrexone in methamphetamine dependence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethamphetamine Dependence
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 1, 2006
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2009
Study CompletionJan 1, 2010
TodayJul 1, 2026
Enrollment to primary: 3.5 yearsPosted 20.1 years ago

Interventions

Naltrexone plus N-Acetyl Cysteinedrug

daily

Placebodrug

daily